Steroids excreted in urine by neonates with 21-hydroxylase deficiency: characterization, using GC-MS and GC-MS/MS, of the D-ring and side chain structure of pregnanes and pregnenes.
Steroid metabolites in urine from neonates with 21-hydroxylase deficiency are predominantly polyhydroxylated 17-hydroxyprogesterone and androgen metabolites, and most have incompletely defined structure. This study forms part of a comprehensive project to characterize and identify these in order to enhance diagnosis and to further elucidate neonatal types of steroid metabolism. Steroids were analyzed, after extraction and enzymatic conjugate hydrolysis, as methyloxime-trimethylsilyl ether derivatives on gas-chromatographs coupled to quadrupole and ion-trap mass-spectrometers. GC-MS and GC-MS/MS spectra, obtained with constant excitation conditions, were used together to determine the structure of the D-ring and the side chain of 20-oxo and 20-hydroxy pregnane(ene)s without oxo groups on the A-, B-, and C-ring. All possible combinations of D-ring and side chain configuration were considered. Most fragmentations could be interpreted as partial or complete D-ring cleavages with loss of the side chain, aided by comparison with spectra of deuterated derivatives and of borohydride reduced metabolites. Possible rearrangement ions are also discussed. More than 140 endogenous metabolites were characterized. GC-MS/MS was especially beneficial for characterization of compounds with 16,17-dihydroxy-20-oxo structure, interpreted as markers of intra-uterine enzyme induction. It also assisted the differentiation of 16-hydroxy-20-oxo metabolites, present in urine of non-affected neonates, from the diagnostic 17-hydroxy-20-oxosteroids and enabled the detection of 15,17-dihydroxy-20-oxo compounds in low concentrations. The presence of 17,21-dihydroxylated pregnane(ene)s despite the deficit in CYP21A2 is discussed. We conclude that GC-MS combined with GC-MS/MS allows reliable identification of the structure of the D-ring and side chain of pregnane(ene)s without prior isolation, even when in low concentrations in urine.
Christakoudi
Sofia
S
Department of Clinical Biochemistry, King's College Hospital, Denmark Hill, London SE5 9RS, UK. hristakudi@doctor.bg
Cowan
David A
DA
Taylor
Norman F
NF
D019326:17-alpha-Hydroxyprogesterone / Q000737:chemistry / Q000378:metabolism; D000312:Adrenal Hyperplasia, Congenital / Q000201:enzymology / Q000235:genetics; D002849:Chromatography, Gas / Q000379:methods*; D008401:Gas Chromatography-Mass Spectrometry / Q000379:methods*; D006801:Humans; D006900:Hydroxylation; D006908:Hydroxyprogesterones / Q000737:chemistry / Q000378:metabolism; D007223:Infant; D007231:Infant, Newborn; D011278:Pregnanes / Q000737:chemistry / Q000378:metabolism / Q000652:urine; D011283:Pregnenes / Q000737:chemistry / Q000378:metabolism / Q000652:urine; D021241:Spectrometry, Mass, Electrospray Ionization / Q000379:methods*; D013255:Steroid 21-Hydroxylase / Q000235:genetics / Q000378:metabolism*; D013256:Steroids / Q000737:chemistry / Q000378:metabolism / Q000652:urine*
D006908:Hydroxyprogesterones; D011278:Pregnanes; D011283:Pregnenes; D013256:Steroids; C018975:16-hydroxyprogesterone; D019326:17-alpha-Hydroxyprogesterone; C531510:CYP21A2 protein, human; D013255:Steroid 21-Hydroxylase